Volt Carbon Technologies Announces Subsidiary Solid Ultrabattery as a Successful Applicant of the DAIR Green Fund

Volt Carbon Technologies Inc. (“Volt Carbon” or the “Company”) (TSX-V: VCT) (OTCQB: TORVF) in conjunction with Downsview Aerospace Innovation & Research (DAIR) is pleased to announce that its subsidiary, Solid Ultrabattery Inc. is a successful applicant of the DAIR Green Fund for a project titled “Development of lithium-ion battery for small drone and UAV applications.” […]

Continue Reading

ProMIS Neurosciences Announces Abstracts Accepted for Presentation at the American Academy of Neurology 2023 Annual Meeting

ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced an oral presentation and two onsite poster presentations at the upcoming American Academy […]

Continue Reading

ProMIS Neurosciences to Present New Preclinical Data for PMN310 at AD/PD 2023

ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that new preclinical data for ProMIS’ lead candidate for AD, PMN310, will be […]

Continue Reading

Leading Tokenization Firm DigiShares Introduces Three New Solutions

DigiShares, a global provider of infrastructure for tokenization of real-world assets, has recently introduced three new configurations of its market leading platform, to cater for three different market segments. This enables DigiShares to support the main three tokenization use cases, crypto-settled, fiat-settled, and internally settled. Each configuration is optimized for full automation and ease of […]

Continue Reading

ProMIS Neurosciences Announces Full Year 2022 Financial Results and Recent Highlights

ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced its full year 2022 financial results and recent highlights.   Completed all preclinical […]

Continue Reading

Promis Neurosciences to Present at the Oppenheimer 33rd Annual Healthcare Conference

ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that Gail Farfel, Ph.D., Chief Executive Officer, will present at the upcoming Oppenheimer […]

Continue Reading